Tesamorelin typically produces measurable visceral fat reduction over 12 to 26 weeks of consistent therapy, with the Phase III trial data showing 15 percent reduction at 26 weeks
The result is a perfect storm where you lose fluids through symptoms, do not feel motivated to replace them, and may not realize you are becoming dehydrated until symptoms become serious
For scale, the approved drugs it would compete with, Lilly's own Zepbound and Novo Nordisk's Wegovy, take off roughly 15% to 21% in their trials
Learn More From Our Specialists Bariatric Surgery in the GLP-1 Era: Who's a Candidate and Is It Safe
For example, semaglutide could be used preoperatively to reduce surgical risk, or postoperatively to maintain weight loss and reduce the likelihood of regain [28,29,30]
Frequently asked questions Is retatrutide better than Wegovy